Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00660764

Acronym

HEROS

Enrollment

Unknown

Registered

2008-04-17

Start date

2003-05-31

Completion date

2005-04-30

Last updated

2009-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Accident, Coronary Heart Disease, Diabetes, Hypercholesterolemia, Peripheral Vascular Disease

Keywords

cholesterol, coronary heart disease, rosuvastatin, LDL-C goal, hypercholesterolemia, secondary prevention, primary prevention, CVA

Brief summary

In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.

Interventions

DRUGRosuvastatin

Oral

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l. * According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. * The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. * Patient approved to place anonymous results at the disposal of AstraZeneca

Exclusion criteria

* Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin

Design outcomes

Primary

Measure	Time frame
Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.	2 year

Secondary

Measure	Time frame
Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026